curl -X POST https://win.oneshotagent.com/v1/tools/lookup/product-drug-label \
  -H "Content-Type: application/json" \
  -H "payment-signature: <base64 x402 payment>" \
  -d '{
    "ndc": "70247-019"
  }'

const response = await fetch("https://win.oneshotagent.com/v1/tools/lookup/product-drug-label", {
  method: "POST",
  headers: {
    "Content-Type": "application/json",
    "payment-signature": paymentProof,
  },
  body: JSON.stringify({
    "ndc": "70247-019"
  }),
});

const result = await agent.tool('lookup/product-drug-label', {
  ndc: '70247-019'
});
console.log(result.result);
console.log(result.evidence);

{
  "success": true,
  "data": {
    "request_id": "uuid",
    "receipt_id": "rcpt_...",
    "status": "completed",
    "tool": "product_drug_label",
    "result": {
      "found": true,
      "total": 1,
      "products": [
        {
          "product_ndc": "70247-019",
          "brand_name": "Metformin Hydrochloride",
          "generic_name": "Metformin Hydrochloride Extended-Release Tablets",
          "labeler": "Qingdao BAHEAL Pharmaceutical Co. Ltd.",
          "active_ingredients": [
            {
              "name": "METFORMIN HYDROCHLORIDE",
              "strength": "500 mg/1"
            }
          ],
          "dosage_form": "TABLET, FILM COATED, EXTENDED RELEASE",
          "routes": [
            "ORAL"
          ],
          "product_type": "HUMAN PRESCRIPTION DRUG",
          "marketing_category": "ANDA",
          "application_number": "ANDA209993",
          "marketing_start": "2018-12-27",
          "marketing_end": null,
          "listing_expires": "2027-12-31",
          "dea_schedule": null,
          "pharm_classes": [
            "Biguanide [EPC]",
            "Biguanides [CS]"
          ],
          "upcs": [
            "0370247018602",
            "0370247019609"
          ],
          "rxcuis": [
            "1807894",
            "1807917"
          ],
          "set_id": "7ea6e623-4073-4671-e053-2a91aa0a3ca3",
          "packages": [
            {
              "package_ndc": "70247-019-60",
              "description": "60 TABLET, FILM COATED, EXTENDED RELEASE in 1 BOTTLE, PLASTIC (70247-019-60)",
              "marketing_start": "2018-12-27",
              "marketing_end": null,
              "sample": false
            }
          ]
        }
      ],
      "label": {
        "set_id": "7ea6e623-4073-4671-e053-2a91aa0a3ca3",
        "document_id": "53f09425-9050-34b0-e063-6394a90a3fb7",
        "version": 5,
        "effective_date": "2026-06-10",
        "sections": {
          "boxed_warning": "WARNING: LACTIC ACIDOSIS Post-marketing cases of metformin-associated lactic acidosis have resulted in death, hypothermia, hypotension, and resistant bradyarrhythmias. The onset of metformin-associated lactic acidosis is often subtle, accompanied only by nonspecific symptoms such as malaise, myalgias, respiratory distress, somnolence, and abdominal pain. Metformin-associated lactic acidosis was characterized by elevated blood lactate levels (> 5 mmol/Liter), anion gap acidosis (without evidence of ketonuria or ketonemia), an increased lactate/pyruvate ratio; and metformin plasma levels generally >5 mcg/mL [ see Warnings and Precautions (5.1) ]. Risk factors for metformin-associated lactic acidosis include renal impairment, concomitant use of certain drugs (e.g., carbonic anhydrase inhibitors such as topiramate), age 65 years old or greater, having a radiological study with contrast, surgery and other procedures, hypoxic states (e.g., acute congestive heart failure), excessive alcohol intake, hepatic impairment, and mitochondrial diseases [see Warnings and precaytions (5.1) ] . Steps to reduce the risk of and manage metformin-associated lactic acidosis in these high risk groups are provided [ see Dosage and Administration (2.2) , Contraindications (4) , Warnings and precaytions (5.1) ]. If metformin-associated lactic acidosis is suspected, immediately discontinue metformin hydrochloride extended-release tablets and institute general supportive measures in a hospital setting. Prompt hemodialysis is recommended [ see Warnings and Precautions(5.1) ]. WARNING: LACTIC ACIDOSIS See full prescribing information for complete boxed warning. Postmarketing cases of metformin-associated lactic acidosis have resulted in death, hypothermia, hypotension, and resistant bradyarrhythmias. Symptoms included malaise, myalgias, respiratory distress, somnolence, and abdominal pain. Laboratory abnormalities included elevated blood lactate levels, anion gap acidosis, increased...",
          "indications_and_usage": "1 INDICATIONS AND USAGE Metformin hydrochloride extended-release tablets are indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus. Metformin hydrochloride extended-release tablets are biguanide indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus. (1)",
          "dosage_and_administration": "2 DOSAGE AND ADMINISTRATION Swallow metformin hydrochloride extended-release tablets whole and never crush, cut or chew (2.1) Starting dose: 500 mg orally once daily with the evening meal (2.1) Increase the dose in increments of 500 mg weekly, up to a maximum of 2,000 mg once daily with the evening meal (2.1) Patients receiving metformin hydrochloride (HCl) tablets may be switched to metformin hydrochloride extended-release tablets once daily at the same total daily dose, up to 2,000 mg once daily (2.1) Renal Impairment: Prior to initiation, assess renal function with estimated glomerular filtration rate (eGFR) (2.2) o Do not use in patients with eGFR below 30 mL/minute/1.73 m 2 (2.2) o Initiation is not recommended in patients with eGFR between 30 to 45 mL/minute/1.73 m 2 (2.2) o Assess risk/benefit of continuing if eGFR falls below 45 mL/minute/1.73 m 2 (2.2) o Discontinue if eGFR falls below 30 mL/minute/1.73 m 2 (2.2) Discontinuation for Iodinated Contrast Imaging Procedures: Metformin hydrochloride extended-release tablets may need to be discontinued at time of, or prior to, iodinated contrast imaging procedures (2.3) 2.1 Adult Dosage and Administration Swallow metformin hydrochloride extended-release tablets whole and never crush, cut or chew. The recommended starting dose of metformin hydrochloride extended-release tablets is 500 mg orally once daily with the evening meal. Increase the dose in increments of 500 mg weekly on the basis of glycemic control and tolerability, up to a maximum of 2,000 mg once daily with the evening meal. If glycemic control is not achieved with metformin hydrochloride extended-release tablets 2,000 mg once daily, consider a trial of metformin hydrochloride extended-release tablets 1,000 mg twice daily. Patients receiving metformin hydrochloride (HCl) may be switched to metformin hydrochloride extended-release tablets once daily at the same total daily dose, up to 2,000 mg once daily. 2.2 Recommendations for Use in Renal Impairment...",
          "contraindications": "4 CONTRAINDICATIONS Metformin hydrochloride extended-release tablets are contraindicated in patients with: Severe renal impairment (eGFR below 30 mL/min/1.73m 2 ) [ see Warnings and Precautions (5.1) ]. Hypersensitivity to metformin. Acute or chronic metabolic acidosis, including diabetic ketoacidosis, with or without coma. Severe renal impairment (eGFR below 30 mL/min/1.73 m 2 ) (4, 5.1) Hypersensitivity to metformin (4) Acute or chronic metabolic acidosis, including diabetic ketoacidosis, with or without coma. (4)",
          "warnings": "5 WARNINGS AND PRECAUTIONS Lactic Acidosis: See boxed warning. (5.1) Vitamin B12 Deficiency: Metformin may lower vitamin B12 levels. Measure hematological parameters annually and vitamin B12 at 2 to 3 year intervals and manage any abnormalities. (5.2) Hypoglycemia with Concomitant Use with Insulin and Insulin Secretagogues: Increased risk of hypoglycemia when used in combination with insulin and/or an insulin secretagogue. Lower dose of insulin or insulin secretagogue may be required. (5.3) 5.1 Lactic Acidosis There have been postmarketing cases of metformin-associated lactic acidosis, including fatal cases. These cases had a subtle onset and were accompanied by nonspecific symptoms such as malaise, myalgias, abdominal pain, respiratory distress, or increased somnolence; however, hypotension and resistant bradyarrhythmias have occurred with severe acidosis. Metformin-associated lactic acidosis was characterized by elevated blood lactate concentrations (> 5 mmol/L), anion gap acidosis (without evidence of ketonuria or ketonemia), and an increased lactate: pyruvate ratio; metformin plasma levels were generally > 5 mcg/mL. Metformin decreases liver uptake of lactate increasing lactate blood levels which may increase the risk of lactic acidosis, especially in patients at risk. If metformin-associated lactic acidosis is suspected, general supportive measures should be instituted promptly in a hospital setting, along with immediate discontinuation of metformin hydrochloride extended-release tablets. In metformin hydrochloride extended-release tablets treated patients with a diagnosis or strong suspicion of lactic acidosis, prompt hemodialysis is recommended to correct the acidosis and remove accumulated metformin (metformin HCl is dialyzable with a clearance of up to 170 mL/min under good hemodynamic conditions). Hemodialysis has often resulted in reversal of symptoms and recovery. Educate patients and their families about the symptoms of lactic acidosis and, if these...",
          "active_ingredient": null,
          "purpose": null,
          "inactive_ingredient": null
        },
        "cut_sections": [
          "boxed_warning",
          "dosage_and_administration",
          "warnings"
        ]
      }
    },
    "evidence": {
      "source": "US Food and Drug Administration",
      "source_kind": "public",
      "retrieved_at": "2026-10-28T20:34:15.316Z",
      "calls": [
        {
          "retrieved_at": "2026-10-28T20:34:15.316Z"
        },
        {
          "retrieved_at": "2026-10-28T20:34:15.316Z"
        }
      ],
      "as_of": "2026-10-28"
    }
  }
}